Redeye updates on Evolution post Q4-results which came in close to our forecasts.
Redeye comments on Coala-Life’s latest development: the company has secured liquidity of cSEK27m thr...
Redeye was impressed by yet another solid quarter from new-old CEO, Anders Lidbeck, who once again b...
Redeye updates its estimates and valuation following Vitec’s Q4 2023 report, featuring solid top-lin...
Redeye comments on the public offering announced today.
Redeye leaves its comments on today's news that Acarix has appointed a new CEO.
Redeye is neutral about the return of the lipodystrophy project, as it does not affect our base case...
Redeye comments on Hoylu’s Q4 2023 report, with figures missing our expectations across the board.
Redeye endorses Iconovo’s new order from a Top-10 pharma company to evaluate a multi-dose inhaler fr...
DT’s Q4 results were somewhat better than estimated.
Sjunkande försäljning, men lönsamhetsförbättring att vänta Inför Q4-rapporten har vi justerat ned vå...
-11% organisk tillväxt… Med volymtillväxt på ca -5% och fallande fraktpriser på 6% var den organiska...
Clean EBIT SEK -100m vs. ABGSCe SEK -20m Q1 likely stronger than Q4 Conference call at 12 CET Clean...
Sales +4% and adj. EBITDA -9% vs. ABGSCe Operating cash flow SEK 157m, vs ABGSCe SEK -1m Expects con...
It was recently reported that Infrahubs had signed an agreement to sell one of its logistics propert...
Redeye comments on Evolution’s Q4-results which were in line with our forecast and the EBITDA-margin...
Redeye comments on last night’s news that the majority shareholders of Netmore have entered into an ...
Elanders presented a decent Q4 2023 report with 13% lower sales y/y, driven by the cocktail of disco...
Still high uncertainty, but Elanders is making improvements.
Continued sequential growth, delivering on cost savings Wind market improving, wind power customers'...
